IL251147B - Condensed pentacyclic imidazole histories - Google Patents
Condensed pentacyclic imidazole historiesInfo
- Publication number
- IL251147B IL251147B IL251147A IL25114717A IL251147B IL 251147 B IL251147 B IL 251147B IL 251147 A IL251147 A IL 251147A IL 25114717 A IL25114717 A IL 25114717A IL 251147 B IL251147 B IL 251147B
- Authority
- IL
- Israel
- Prior art keywords
- imidazole derivatives
- fused pentacyclic
- pentacyclic imidazole
- fused
- derivatives
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290299 | 2014-10-03 | ||
| EP15162641 | 2015-04-07 | ||
| EP15171036 | 2015-06-08 | ||
| PCT/EP2015/072868 WO2016050975A1 (en) | 2014-10-03 | 2015-10-02 | Fused pentacyclic imidazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL251147A0 IL251147A0 (en) | 2017-04-30 |
| IL251147B true IL251147B (en) | 2020-05-31 |
Family
ID=54238452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251147A IL251147B (en) | 2014-10-03 | 2017-03-14 | Condensed pentacyclic imidazole histories |
Country Status (36)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40770B1 (fr) * | 2014-10-03 | 2021-11-30 | Sanofi Sa | Dérivés d'imidazoles pentacyclic fusionnés |
| US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| UY36628A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| WO2016168641A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| WO2017167996A1 (en) | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| BR112018069936A2 (pt) | 2016-04-01 | 2019-02-05 | Sanofi Sa | derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf |
| US10654861B2 (en) | 2016-04-01 | 2020-05-19 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
| EA201892144A1 (ru) * | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf |
| GB201620948D0 (en) | 2016-12-09 | 2017-01-25 | Ucb Biopharma Sprl | Therapeutic agents |
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| JP7121033B2 (ja) * | 2017-03-15 | 2022-08-17 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 |
| MA49055B1 (fr) * | 2017-04-25 | 2021-12-31 | Sanofi Sa | Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf |
| MX2020010433A (es) * | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
| ES2951837T3 (es) * | 2018-10-24 | 2023-10-25 | UCB Biopharma SRL | Derivados de imidazol pentacíclicos condensados como moduladores de la actividad de TNF |
| CN113683505A (zh) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | 一种含氧代环丁基的羧酸酯类化合物的制备方法 |
| JP2025540024A (ja) * | 2022-11-23 | 2025-12-11 | フォワード セラピューティクス， インコーポレイテッド | ＴＮＦ－α活性の調節因子 |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| US20260028348A1 (en) * | 2023-01-05 | 2026-01-29 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| TW202508596A (zh) | 2023-04-26 | 2025-03-01 | 法商賽諾菲公司 | 使用腫瘤壞死因子α之小分子抑制劑治療乾癬 |
| TW202513567A (zh) * | 2023-06-09 | 2025-04-01 | 大陸商上海翰森生物醫藥科技有限公司 | 五環類衍生物抑制劑、其製備方法與應用 |
| TW202521544A (zh) | 2023-08-16 | 2025-06-01 | 美商雷瑟拉股份有限公司 | TNFα活性調節劑及其用途 |
| WO2025068505A1 (en) | 2023-09-29 | 2025-04-03 | Sanofi | Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation |
| WO2025137267A1 (en) * | 2023-12-21 | 2025-06-26 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025201449A1 (zh) * | 2024-03-27 | 2025-10-02 | 海思科医药集团股份有限公司 | 一种杂环衍生物及其在医药上的应用 |
| WO2025212627A1 (en) | 2024-04-03 | 2025-10-09 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025218735A1 (zh) * | 2024-04-17 | 2025-10-23 | 上海翰森生物医药科技有限公司 | 五环类衍生物抑制剂、其制备方法和应用 |
| WO2025244936A1 (en) * | 2024-05-20 | 2025-11-27 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025247401A1 (zh) * | 2024-05-31 | 2025-12-04 | 海思科医药集团股份有限公司 | 一种稠合杂环衍生物及其在医药上的应用 |
| WO2025255096A1 (en) * | 2024-06-03 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Cycloalkyl and heterocyclic modulators of tnf activity |
| WO2025252251A1 (zh) * | 2024-06-07 | 2025-12-11 | 上海翰森生物医药科技有限公司 | 含氧杂环类衍生物抑制剂、其制备方法和应用 |
| WO2026022134A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Novel aminocarbonylation processes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449649A3 (en) | 1990-03-30 | 1992-09-02 | Arizona Board Of Regents, Arizona State University | Antineoplastic quinones and methods of using same |
| FR2832711B1 (fr) | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| BRPI0408477A (pt) | 2003-03-10 | 2006-04-04 | Pfizer | compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| ES2576298T3 (es) | 2011-06-20 | 2016-07-06 | Vertex Pharmaceuticals Incorporated | Ésteres de fosfato de inhibidores de girasa y topoisomerasa |
| TR201807207T4 (tr) * | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| JP6259823B2 (ja) | 2012-07-13 | 2018-01-10 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性の調節物質としてのイミダゾピリジン誘導体 |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| KR101862493B1 (ko) | 2013-10-25 | 2018-05-29 | 노파르티스 아게 | Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체 |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| MA40770B1 (fr) * | 2014-10-03 | 2021-11-30 | Sanofi Sa | Dérivés d'imidazoles pentacyclic fusionnés |
-
2015
- 2015-10-02 MA MA40770A patent/MA40770B1/fr unknown
- 2015-10-02 DK DK15771976.6T patent/DK3201196T3/da active
- 2015-10-02 UY UY0001036341A patent/UY36341A/es not_active Application Discontinuation
- 2015-10-02 TW TW104132631A patent/TWI719949B/zh active
- 2015-10-02 UA UAA201702002A patent/UA120764C2/uk unknown
- 2015-10-02 JP JP2017518131A patent/JP6629847B2/ja active Active
- 2015-10-02 EA EA201790734A patent/EA032839B1/ru not_active IP Right Cessation
- 2015-10-02 WO PCT/EP2015/072868 patent/WO2016050975A1/en not_active Ceased
- 2015-10-02 PL PL15771976T patent/PL3201196T3/pl unknown
- 2015-10-02 AP AP2017009809A patent/AP2017009809A0/en unknown
- 2015-10-02 SI SI201531711T patent/SI3201196T1/sl unknown
- 2015-10-02 HU HUE15771976A patent/HUE056133T2/hu unknown
- 2015-10-02 CA CA2962826A patent/CA2962826C/en active Active
- 2015-10-02 ES ES15771976T patent/ES2885432T3/es active Active
- 2015-10-02 EP EP15771976.6A patent/EP3201196B1/en active Active
- 2015-10-02 SG SG11201701796XA patent/SG11201701796XA/en unknown
- 2015-10-02 PE PE2017000544A patent/PE20170693A1/es unknown
- 2015-10-02 RS RS20211235A patent/RS62423B1/sr unknown
- 2015-10-02 TN TN2017000083A patent/TN2017000083A1/en unknown
- 2015-10-02 HR HRP20211605TT patent/HRP20211605T1/hr unknown
- 2015-10-02 MY MYPI2017701132A patent/MY181019A/en unknown
- 2015-10-02 BR BR112017006669-6A patent/BR112017006669B1/pt active IP Right Grant
- 2015-10-02 KR KR1020177011958A patent/KR102442235B1/ko active Active
- 2015-10-02 US US15/513,357 patent/US10202405B2/en active Active
- 2015-10-02 AU AU2015326798A patent/AU2015326798B2/en active Active
- 2015-10-02 CR CR20170167A patent/CR20170167A/es unknown
- 2015-10-02 LT LTEPPCT/EP2015/072868T patent/LT3201196T/lt unknown
- 2015-10-02 CN CN201580053711.8A patent/CN107108672B/zh active Active
- 2015-10-02 MX MX2017004201A patent/MX380578B/es unknown
-
2017
- 2017-03-06 PH PH12017500414A patent/PH12017500414B1/en unknown
- 2017-03-07 GT GT201700044A patent/GT201700044A/es unknown
- 2017-03-14 IL IL251147A patent/IL251147B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01946A patent/ZA201701946B/en unknown
- 2017-03-31 CL CL2017000787A patent/CL2017000787A1/es unknown
- 2017-04-06 CO CONC2017/0003331A patent/CO2017003331A2/es unknown
- 2017-05-03 EC ECIEPI201727306A patent/ECSP17027306A/es unknown
-
2018
- 2018-12-14 US US16/220,847 patent/US10906919B2/en active Active
-
2020
- 2020-11-24 US US17/102,790 patent/US11912721B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201701946B (en) | Fused pentacyclic imidazole derivatives | |
| IL291598A (en) | History of benzodiazepine cytotoxicity | |
| IL253381B (en) | History of h9–pyrrolo–dipyridine | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| PL3418273T3 (pl) | Pochodne flawaglin | |
| EP3099672A4 (en) | Fused imidazole compounds | |
| HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
| IL248773A0 (en) | History of naphthyridinedione | |
| IL251005B (en) | Pyrido-oxazinone derivatives | |
| ZA201605243B (en) | Ethynyl derivatives | |
| SG11201608634RA (en) | Cycloalkyl-linked diheterocycle derivatives | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| GB201414116D0 (en) | Benzodiazepine derivatives | |
| PT3228616T (pt) | Derivados de piridina | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| PT3201196T (pt) | Derivados de imidazol pentacíclicos fusionados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |